Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) just unveiled an update.
ASKA Pharmaceutical Co., Ltd., in collaboration with Daiichi Sankyo Healthcare, has obtained marketing authorization for the emergency contraceptive pill NORLEVO® to be sold over-the-counter (OTC) in Japan. This move aims to empower women by enhancing accessibility to reproductive health products, marking a significant milestone in sexual reproductive health and rights. The impact on the company’s financial year 2025 is under evaluation, and further details on product specifications and sales timing will be announced later.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2590.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of prescription and over-the-counter (OTC) medications. The company is involved in advancing sexual reproductive health and rights, particularly through products like emergency contraceptive pills.
Average Trading Volume: 70,086
Technical Sentiment Signal: Sell
Current Market Cap: Yen56.29B
Learn more about 4886 stock on TipRanks’ Stock Analysis page.